Markets
Leaderboard
Will LY-CoV555 be effective in temporarily immunizing people against SARS-COV-2? Yes: real money —, play money 50% No: real money —, play money 50% Volume: real money —, play money — Bettors: real money 0, play money 0 Categories: Science, Transmissible Diseases, Covid-19 (Coronavirus), Treatments Related markets Nipah virus declared a public health emergency by the WHO in 2026? (ID: 233776) Volume: real 100.18015496, play 14933.4347 Bettors: real 4, play 3 Leading (real money): Nipah virus declared a public health emergency by the WHO in 2026? 11% Leading (play money): Nipah virus declared a public health emergency by the WHO in 2026? 6% Antarctic sea ice minimum to decrease in 2027? (ID: 235045) Volume: real 500.10026694, play 50000 Bettors: real 4, play 0 Leading (real money): Antarctic sea ice minimum to decrease in 2027? 81% Leading (play money): Antarctic sea ice minimum to decrease in 2027? 81%

Will LY-CoV555 be effective in temporarily immunizing people against SARS-COV-2?

Market Rules

Researchers at the American pharmaceutical company Eli Lilly & Co are developing an experimental treatment against SARS-Cov-2 using synthetic antibodies. The idea of the drug is not to provide long-term immunity, but to be an additional protection for health professionals, the most vulnerable patients, and people who need to have contact with the public or infected people.

Like natural antibodies, this synthetic antibody must connect to the virus and block it. The drug, called LY-CoV555, is in phase III testing in humans, and results are expected by the end of 2020.

If the drug LY-CoV555 proves to be effective in temporarily providing immunity to people against SARS-COV-2 by the end of 2020 - and such efficacy is confirmed by the scientific community - this market will be resolved as “Yes”.

Related Markets